TikoMed AB, is a biopharmaceutical company focused on bringing project from early preclinical PoC to PoC in man. Presently the company is pursuing the development of IBsolvMIR®, a drug that promotes efficacy in cell-therapy by protecting and promoting engraftment of therapeutic cells. The drug has an excellent safety profile and has undergone Phase 2 studies in islet transplantation.

Contact TikoMed
+46 (0)708-238444
adam.bruce@tikomed.com
Visit Website